Close Menu

NEW YORK – GeneCentric Therapeutics said on Wednesday that it is entering a research collaboration with Janssen Research & Development around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).

Using GeneCentric's RNA-based molecular profiling platform, the partners will identify potential signatures of disease progression and drug response to standard-of-care therapy, including the role of genomic alterations in the fibroblast growth factor receptor (FGFR), which are among the more common tumor mutations in these patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.